Page last updated: 2024-09-05

deferasirox and Anemias, Iron-Deficiency

deferasirox has been researched along with Anemias, Iron-Deficiency in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Kondo, T; Miyake, Z; Nakamagoe, K; Tamaoka, A; Yoshida, K	1
Bedford, MR; Ford, SJ; Iqbal, T; Pang, W; Tselepis, C; Tucker, O; Wood, A	1
Batty, KT; Ferrari, P; Maker, GL; Olynyk, JK; Siva, B; Trengove, RD	1

Reviews

1 review(s) available for deferasirox and Anemias, Iron-Deficiency

Article	Year
Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature. Internal medicine (Tokyo, Japan), 2020, Jul-15, Volume: 59, Issue:14 Topics: Adult; Anemia, Iron-Deficiency; Ceruloplasmin; Copper; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Neurodegenerative Diseases; Treatment Outcome; Young Adult	2020

Article

Year

Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature.

Internal medicine (Tokyo, Japan), 2020, Jul-15, Volume: 59, Issue:14

Topics: Adult; Anemia, Iron-Deficiency; Ceruloplasmin; Copper; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Male; Middle Aged; Neurodegenerative Diseases; Treatment Outcome; Young Adult

2020

Trials

1 trial(s) available for deferasirox and Anemias, Iron-Deficiency

Article	Year
Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:3 Topics: Aged; Anemia, Iron-Deficiency; Area Under Curve; Benzoates; Biological Availability; Chromatography, Liquid; Deferasirox; Drug Administration Schedule; Drug Monitoring; Female; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pilot Projects; Renal Dialysis; Renal Insufficiency, Chronic; Tandem Mass Spectrometry; Triazoles; Western Australia	2013

Article

Year

Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.

Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:3

Topics: Aged; Anemia, Iron-Deficiency; Area Under Curve; Benzoates; Biological Availability; Chromatography, Liquid; Deferasirox; Drug Administration Schedule; Drug Monitoring; Female; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Pilot Projects; Renal Dialysis; Renal Insufficiency, Chronic; Tandem Mass Spectrometry; Triazoles; Western Australia

2013

Other Studies

1 other study(ies) available for deferasirox and Anemias, Iron-Deficiency

Article	Year
A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy. Annals of the Royal College of Surgeons of England, 2014, Volume: 96, Issue:4 Topics: Adenocarcinoma; Aged; Anemia, Iron-Deficiency; Benzoates; Chelation Therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deferasirox; Esophageal Neoplasms; Esophagectomy; Female; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Male; Patient Selection; Prospective Studies; Triazoles	2014

Article

Year

A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

Annals of the Royal College of Surgeons of England, 2014, Volume: 96, Issue:4

Topics: Adenocarcinoma; Aged; Anemia, Iron-Deficiency; Benzoates; Chelation Therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deferasirox; Esophageal Neoplasms; Esophagectomy; Female; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Male; Patient Selection; Prospective Studies; Triazoles

2014